China's drug regulator approved Shanghai Shyndec Pharmaceutical's (SHA:600420) tafluprost eye drops, according to a Tuesday filing with the Shanghai boures.
The drops help lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension.